title: Allogeneic stem cell transplantation for myelofibrosis in 2012.
abstract: Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of conditioning regimen. This review summarizes key findings from published data concerning AHSCT in MF and attempts to provide a state of the art approach to MF-AHSCT in 2012. In addition, we postulate on how the era of JAK inhibition might impact on transplantation for MF.
authors.affiliation: Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK. donal.mclornan@nhs.net
authors.forename: Donal P
authors.initials: DP
authors.lastname: McLornan
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Mead
authors.forename: Graham
authors.initials: G
authors.lastname: Jackson
authors.forename: Claire N
authors.initials: CN
authors.lastname: Harrison
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics; D009154:Mutation; D055728:Primary Myelofibrosis / Q000235:genetics / Q000628:therapy*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D013156:Splenectomy; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D057832:Watchful Waiting
chemical_list: D047428:Protein Kinase Inhibitors; D053614:Janus Kinase 2